Table 1: Participants’ characteristics and medication.

PD subject Age (years) Gender Disease duration (years)UPDRSUPDRSNeuroFlexor  LED
Hoehn and Yahr scale ()Part III score ()MA arm Rigidity MA ()Rigidity LATOT MA (N) ()TOT LA (N)

169M7230R216.47.0400
273F2227L116.08.5500
372F4449 L2213.711.41605
466F1216R117.97.3200
572F112R1010.77.6300
663F115R 105.84.6600
767F7213L 118.89.5823
871M4346L 3116.17.1599
979M2111R 106.85.1300
1081M5119 R 2013.64.1200
1177M3221R 218.05.6500
1273F7445L 2213.119.61475
1369M3113R 20 8.16.4575
1478M8 341L 337.211.7575
1577M5339L 2218.130.11000
1666M11340L 3214.214.91651
1772F18324L 213.34.6873
1856M20 243L 3221.326.11075
1973M18215L 3210.310.2733
2076M9 28 R 106.95.21149
2173M13333R 3221.312.4798
2278F5325L 219.87.5480
2380M6328 R 10 8.65.1775
2479M10345R 2224.15.9900
2567M5217R 215.85.5557

Mean ± SD72.3  ±  6.07.0  ±  5.42  ±  126  ±  1411.0  ±  5.59.7  ±  6.6746  ±  404
M: 16 
F: 9
R: 13 
L: 12
Median: 2Median: 1

PD: Parkinson’s disease, M: male, F: female, R: right, L: left, MA: most affected, LA: least affected, N: Newton, and LED: levodopa equivalent dose [25].
() Disease rating 1–5 according to Hoehn and Yahr scale.
() Unified Parkinson’s disease rating scale, motor section, maximum 108 p.
() Rigidity according to UPDRS: 0 = absent; 1 = slight or detectable only when activated by mirror or other movements; 2 = mild to moderate; 3 = marked; 4 = severe.
() Total resistance in NeuroFlexor measurements, mean of passive and dynamic condition.